Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NYSE:ERF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$21.60+35.8%$7.04$4.92▼$25.58$8.70M1.34171,493 shs1.08 million shsERFEnerplus$20.09$20.06$13.46▼$20.97$4.10B1.973.07 million shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+11.03%+67.37%+136.61%+188.07%+100.74%ERFEnerplus0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.2907 of 5 stars2.85.00.00.02.40.00.6ERFEnerplusN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.60Strong Buy$25.0015.74% UpsideERFEnerplus 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ARTL, EGH, ERF, AFA, and PNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.006/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.004/28/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/AERFEnerplus$1.69B2.42$4.23 per share4.75$6.10 per share3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$17.940.00N/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)ERFEnerplus$456.08M$1.8011.169.34N/A24.09%33.88%19.89%N/ALatest ARTL, EGH, ERF, AFA, and PNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ARTLArtelo Biosciences-$0.78-$4.32-$3.54-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AERFEnerplus$0.261.29%N/A14.44%1 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.490.49ERFEnerplus0.080.700.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%ERFEnerplus58.42%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%ERFEnerplus0.41%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5550,000542,000Not OptionableERFEnerplus404204.25 million203.41 millionOptionableARTL, EGH, ERF, AFA, and PNS HeadlinesRecent News About These CompaniesEnerplus Corp Book Value / ShareJanuary 27, 2025 | investing.comOil, gas company Enerplus closing Denver office, cutting 73 jobs after mergerNovember 7, 2024 | denverpost.comDIs Chord Energy Corporation (CHRD) Set to Explode in 2025?October 31, 2024 | msn.comRBC Capital bevestigt Outperform-rating voor Chord Energy-aandeel voorafgaand aan Q3-resultatenOctober 7, 2024 | nl.investing.com7 Best Small Company Stocks To Invest InSeptember 28, 2024 | insidermonkey.comChord Energy Corp (CHRD): A Good Beaten Down Stock to Invest InSeptember 5, 2024 | msn.comDelay means major household waste incinerator will not be fully running until 2029August 18, 2024 | uk.news.yahoo.comChord Energy and Enerplus Complete Combination, Creating Premier Williston-Focused E&P CompanyMay 31, 2024 | prnewswire.comEnerplus Corporation (ERF.TO)May 24, 2024 | ca.finance.yahoo.comEnerplus-Chord Energy deal receives shareholder and Investment Canada Act approvalMay 24, 2024 | ca.finance.yahoo.comEnerplus Announces Shareholder Approval of Transaction with Chord Energy Corporation and Receipt of Investment Canada Act ApprovalMay 24, 2024 | finance.yahoo.comEnerplus Corporation (NYSE:ERF) stock is trading -4.60 percent below its 52-week highMay 18, 2024 | bovnews.comBERF Stock Earnings: Enerplus Beats EPS for Q1 2024May 9, 2024 | investorplace.comEnerplus Announces its Quarterly Cash Dividend for June 2024May 8, 2024 | finance.yahoo.comReturns on Capital Paint A Bright Future For Enerplus (TSE:ERF)May 8, 2024 | finance.yahoo.comToronto market subdued as broad gains countered by resource lossesApril 29, 2024 | msn.comEnerplus Announces Filing of Management Information Circular for Special Meeting of ShareholdersApril 25, 2024 | finance.yahoo.comEnerplus (ERF) Advances But Underperforms Market: Key FactsApril 23, 2024 | zacks.comEnerplus (ERF) Crossed Above the 20-Day Moving Average: What That Means for InvestorsApril 23, 2024 | zacks.comENERPLUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enerplus Corporation - ERFApril 15, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Reasons AMD Could Be the Hottest Stock of the SummerBy Sam Quirke | June 20, 2025View 3 Reasons AMD Could Be the Hottest Stock of the SummerMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceAnalyst Downgrades Joby, But Overlooks Major Regulatory WinsBy Jeffrey Neal Johnson | June 17, 2025View Analyst Downgrades Joby, But Overlooks Major Regulatory WinsMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayTop 3 Silver Picks to Watch as Bull Market Gains SteamBy Chris Markoch | June 18, 2025View Top 3 Silver Picks to Watch as Bull Market Gains SteamARTL, EGH, ERF, AFA, and PNS Company DescriptionsArtelo Biosciences NASDAQ:ARTL$21.60 +5.70 (+35.85%) Closing price 04:00 PM EasternExtended Trading$21.52 -0.08 (-0.35%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Enerplus NYSE:ERFEnerplus Corporation, together with its subsidiaries, explores and develops crude oil and natural gas in the United States. Its oil and natural gas properties are located primarily in North Dakota, Colorado, and Pennsylvania. The company was founded in 1986 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
